单次氯胺酮输注联合动机增强疗法治疗酒精使用障碍:一项随机咪达唑仑对照初步试验
该初步试验将40名酒精依赖成人随机分配至单次亚麻醉剂量氯胺酮(0.71 mg/kg)或活性对照咪达唑仑(0.025 mg/kg)输注,均在接受5周门诊动机增强疗法第2周时给药。氯胺酮显著提高戒酒可能性、延迟复发时间并减少重度饮酒天数,输注耐受良好。
要点
- 单次氯胺酮输注联合动机增强疗法可提高酒精依赖患者戒酒可能性。
- 氯胺酮较咪达唑仑延迟复发时间并减少重度饮酒天数。
- 输注耐受良好,无因不良事件退出研究者。
核心结论
- 单次氯胺酮输注可改善接受动机增强疗法的酒精依赖者的饮酒指标。
- 初步数据提示整合药物-行为治疗酒精使用障碍的新方向,需更大样本重复验证。
研究设计与样本
- 随机、活性对照(咪达唑仑)初步试验,共40名酒精依赖成人。
- 氯胺酮组17人接受0.71 mg/kg、52分钟静脉输注,咪达唑仑组23人接受0.025 mg/kg。
- 输注在5周门诊动机增强疗法第2周提供,输注后21天用时间线回溯法评估饮酒,尿乙基葡萄糖醛酸确认戒酒。
主要发现
- 参与者平均年龄53岁(SD=9.8),70.3%为白人,71.8%在职,入组前平均每日饮酒5杯。
- 氯胺酮较咪达唑仑显著提高戒酒可能性、延迟复发时间并减少重度饮酒天数。
- 输注耐受良好,无参与者因不良事件被剔除。
临床怎么用
- 在动机增强疗法背景下,可考虑单次亚麻醉剂量氯胺酮输注作为酒精依赖的辅助治疗选择。
- 治疗决策需结合初步证据级别,并监测输注安全性。
局限性
- 为初步试验,样本量小(N=40),结果需更大样本重复验证。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pharmacotherapy and behavioral treatments for alcohol use disorder are limited in their effectiveness, and new treatments with innovative mechanisms would be valuable. In this pilot study, the authors tested whether a single subanesthetic infusion of ketamine administered to adults with alcohol dependence and engaged in motivational enhancement therapy affects drinking outcomes. METHODS: Participants were randomly assigned to a 52-minute intravenous administration of ketamine (0.71 mg/kg, N=17) or the active control midazolam (0.025 mg/kg, N=23), provided during the second week of a 5-week outpatient regimen of motivational enhancement therapy. Alcohol use following the infusion was assessed with timeline followback method, with abstinence confirmed by urine ethyl glucuronide testing. A longitudinal logistic mixed-effects model was used to model daily abstinence from alcohol over the 21 days after ketamine infusion. RESULTS: Participants (N=40) were mostly middle-aged (mean age=53 years [SD=9.8]), predominantly white (70.3%), and largely employed (71.8%) and consumed an average of five drinks per day prior to entering the study. Ketamine significantly increased the likelihood of abstinence, delayed the time to relapse, and reduced the likelihood of heavy drinking days compared with midazolam. Infusions were well tolerated, with no participants removed from the study as a result of adverse events. CONCLUSIONS: A single ketamine infusion was found to improve measures of drinking in persons with alcohol dependence engaged in motivational enhancement therapy. These preliminary data suggest new directions in integrated pharmacotherapy-behavioral treatments for alcohol use disorder. Further research is needed to replicate these promising results in a larger sample.
引用
- Dakwar E, Levin F, Hart CL, et al. A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. Am J Psychiatry. 2019. PMID: 31786934. doi:10.1176/appi.ajp.2019.19070684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。